EUVIMEDEUVIMED entdecken
Klinische Studie (Phase II)Randomisierte kontrollierte StudieOpen Access · CC BY-NC-ND 4.0

Update on safety and feasibility of the combination of pembrolizumab and pelvic chemoradiation in locally advanced cervical cancer

Linda R Duska iD, Gina R Petroni, Premal H Thaker, Erin K Crane, Laura L Holman, Debrorah K Armstrong, Kara Romano, Jennifer Scalici

Cancer · 2025

DOI: 10.1002/cncr.35757 ↗

Kurz gefasst

Klinische Studie (Phase II) in der Zeitschrift Cancer, 2025. Verfasst von Linda R Duska und 7 weiteren Autor:innen. Beteiligte Einrichtung: Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of Virginia School of Medicine, Charlottesville, Virginia, USA. Hauptthemen laut MEDLINE: Uterine Cervical Neoplasms, Antibodies, Monoclonal, Humanized, Chemoradiotherapy, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 16 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NCI NIH HHS, Merck Sharp and Dohme.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The addition of immune checkpoint inhibitors to standard‐of‐care chemoradiation (CRT) is established as the new standard of care in high‐risk, locally advanced cervical cancer. However, the optimal sequencing of therapies is unknown. Defining safety and feasibility of the combination was a primary objective of this study examining concurrent versus sequential schedules.

Methods

Pembrolizumab was given after or during CRT in a randomized phase 2 design. Patients aged 18 years and older with locally advanced cervical cancer, stages IB–IVA (according to 2009 International Federation of Gynecology and Obstetrics staging) were randomized 1:1 to treatment regimens. CRT was identical for both arms. Pembrolizumab was administered every 3 weeks for three doses; no maintenance was allowed. Safety assessments included the incidence and severity of adverse events (AEs), and feasibility was measured by the completion of treatment in a predefined timeframe. Translational specimens (blood and tissue) were collected.

Results

In total, 94 evaluable patients completed treatment. Treatment‐related grade ≥2 toxicity was experienced by 85 of 94 patients (90%); 40 patients (43%) had at least one grade 3 AE, and 22 (23%) had at least one grade 4 AE. There were no grade 5 AEs. Eighty percent of patients completed radiotherapy within 56 days, and 85% completed five or six doses of cisplatin and three doses of pembrolizumab (74 of 94 patients; 79%).

Conclusions

The final results of this study support the safety and feasibility of adding pembrolizumab to pelvic CRT, concurrently and sequentially. Progression‐free and overall survival were not affected or different between treatment arms. An analysis of the translational end points is ongoing and will inform future study designs.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Uterine Cervical NeoplasmsAntibodies, Monoclonal, HumanizedChemoradiotherapyAntineoplastic Combined Chemotherapy ProtocolsHumansFemaleMiddle AgedAdultAgedFeasibility StudiesNeoplasm StagingAntineoplastic Agents, Immunological

Stichwörter der Autor:innen

cervical cancerchemoradiationfeasibilityimmunotherapysafety

Substanzen

pembrolizumabAntibodies, Monoclonal, HumanizedAntineoplastic Agents, Immunological

Autor:innen und Institutionen

  • Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of Virginia School of Medicine, Charlottesville, Virginia, USA.
  • Department of Public Health Sciences, University of Virginia School of Medicine, Charlottesville, Virginia, USA.
  • Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Washington University School of Medicine and Siteman Cancer Center, St Louis, Missouri, USA.
  • Department of Obstetrics and Gynecology, Atrium Health Wake Forest Baptist Healthcare System, Charlotte, North Carolina, USA.
  • Stephenson Cancer Center, College of Medicine, University of Oklahoma Health Sciences, Oklahoma City, Oklahoma, USA.
  • Medical Oncology, Johns Hopkins School of Medicine, Baltimore, Maryland, USA.

ORCID-Profile: Linda R Duska

Förderung

  • NCI NIH HHS
  • Merck Sharp and Dohme

Zitieren

APA

Duska, L. R., Petroni, G. R., Thaker, P. H., Crane, E. K., Holman, L. L., Armstrong, D. K., Romano, K., & Scalici, J. (2025). Update on safety and feasibility of the combination of pembrolizumab and pelvic chemoradiation in locally advanced cervical cancer. Cancer. https://doi.org/10.1002/cncr.35757

Vancouver

Duska LR, Petroni GR, Thaker PH, Crane EK, Holman LL, Armstrong DK, et al. Update on safety and feasibility of the combination of pembrolizumab and pelvic chemoradiation in locally advanced cervical cancer. Cancer. 2025. doi:10.1002/cncr.35757

BibTeX
@article{Duska2025,
  author = {Duska, Linda R and Petroni, Gina R and Thaker, Premal H and Crane, Erin K and Holman, Laura L and Armstrong, Debrorah K and Romano, Kara and Scalici, Jennifer},
  title = {Update on safety and feasibility of the combination of pembrolizumab and pelvic chemoradiation in locally advanced cervical cancer},
  journal = {Cancer},
  year = {2025},
  doi = {10.1002/cncr.35757}
}
Kostenlos starten →